Latest for Congenital Adrenal Hyperplasia
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
More about Congenital Adrenal Hyperplasia
The 21-hydroxylase enzyme deficiency blocks cortisol synthesis at a critical step, causing shunting of precursors into androgen production, resulting in excessive androgens and combined glucocorticoid and mineralocorticoid deficiency. Three distinct clinical phenotypes exist: salt-wasting (most severe, presenting at 1-4 weeks with hyponatremia, hyperkalemia, and circulatory collapse), simple virilizing (androgen excess without salt wasting, manifesting at birth or early childhood), and non-classic (mild or late-onset androgen excess).
Keep reading about Congenital Adrenal Hyperplasia
Newborn females with classic forms show external virilization including clitoromegaly, labial fusion, and potential ambiguous genitalia. Males may present with precocious puberty or salt-wasting crisis. Without treatment, salt-wasting CAH is life-threatening; all forms require lifelong hormone replacement and monitoring.
What are the symptoms of Congenital Adrenal Hyperplasia?
These are common symptoms of Congenital Adrenal Hyperplasia, and how strong they are varies from person to person.
- Genitals that look more male-typical in female newborns (virilization)
- Salt-wasting crisis in severe forms (hyponatremia, hyperkalemia)
- Precocious puberty and rapid growth in males
- Accelerated linear growth in childhood
- Acne and male-pattern baldness
- Infertility and reproductive dysfunction
Who gets Congenital Adrenal Hyperplasia?
CAH shows autosomal recessive inheritance, affecting males and females equally across all populations. MedlinePlus Genetics puts the classic form at about 1 in 15,000 newborns and the milder non-classic form at about 1 in 1,000 people, and both vary by population. NORD reports the highest known rate among the Yupik people of Alaska, where the salt-wasting form may affect as many as 1 in 282.
Manifestations appear in neonates and early infants (salt-wasting forms) or early childhood (simple virilizing forms). Non-classic forms may present in adolescence or adulthood during reproductive years, particularly in females with irregular menses or hirsutism. Genetic counseling indicates 25% recurrence risk in subsequent pregnancies if both parents are identified carriers.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Congenital Adrenal Hyperplasia?
There are currently 3 FDA-approved medications for Congenital Adrenal Hyperplasia.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Congenital Adrenal Hyperplasia treatment
Charity funds and drugmaker programs for Congenital Adrenal Hyperplasia, checked at the source.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Congenital Adrenal Hyperplasia
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Congenital Adrenal Hyperplasia resources
Reputable organizations and medical references for learning more about Congenital Adrenal Hyperplasia, including disease registries, foundation resources, and clinical guidelines.